^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Prolia (denosumab) (RANK ligand inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Published date:
01/18/2022
Excerpt:
Two Phase III studies of adjuvant denosumab did not show a consistent reduction of breast cancer recurrence in any subset of patients with early-stage breast cancer….The Panel does not recommend the use of adjuvant denosumab…
DOI:
10.1200/JCO.21.02647
